These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women. Iversen OE; Miranda MJ; Ulied A; Soerdal T; Lazarus E; Chokephaibulkit K; Block SL; Skrivanek A; Nur Azurah AG; Fong SM; Dvorak V; Kim KH; Cestero RM; Berkovitch M; Ceyhan M; Ellison MC; Ritter MA; Yuan SS; DiNubile MJ; Saah AJ; Luxembourg A JAMA; 2016 Dec; 316(22):2411-2421. PubMed ID: 27893068 [TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine. Garland SM; Cheung TH; McNeill S; Petersen LK; Romaguera J; Vazquez-Narvaez J; Bautista O; Shields C; Vuocolo S; Luxembourg A Vaccine; 2015 Nov; 33(48):6855-64. PubMed ID: 26411885 [TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and Safety of a 9-Valent HPV Vaccine. Van Damme P; Olsson SE; Block S; Castellsague X; Gray GE; Herrera T; Huang LM; Kim DS; Pitisuttithum P; Chen J; Christiano S; Maansson R; Moeller E; Sun X; Vuocolo S; Luxembourg A Pediatrics; 2015 Jul; 136(1):e28-39. PubMed ID: 26101366 [TBL] [Abstract][Full Text] [Related]
5. Evaluation on the persistence of anti-HPV immune responses to the quadrivalent HPV vaccine in Chinese females and males: Up to 3.5 years of follow-up. Huang T; Liu Y; Li Y; Liao Y; Shou Q; Zheng M; Liao X; Li R Vaccine; 2018 Mar; 36(11):1368-1374. PubMed ID: 29428178 [TBL] [Abstract][Full Text] [Related]
6. Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up. Olsson SE; Restrepo JA; Reina JC; Pitisuttithum P; Ulied A; Varman M; Van Damme P; Moreira ED; Ferris D; Block S; Bautista O; Gallagher N; McCauley J; Luxembourg A Papillomavirus Res; 2020 Dec; 10():100203. PubMed ID: 32659510 [TBL] [Abstract][Full Text] [Related]
7. Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial. Krajden M; Cook D; Yu A; Chow R; Su Q; Mei W; McNeil S; Money D; Dionne M; Palefsky J; Karunakaran K; Kollmann T; Ogilvie G; Petric M; Dobson S Vaccine; 2014 Jan; 32(5):624-30. PubMed ID: 24055350 [TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccine versus two doses of nonavalent vaccine - A randomized clinical trial. Gilca V; Sauvageau C; Panicker G; De Serres G; Ouakki M; Unger ER Vaccine; 2018 Nov; 36(46):7017-7024. PubMed ID: 30314913 [TBL] [Abstract][Full Text] [Related]
9. A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls. Vesikari T; Brodszki N; van Damme P; Diez-Domingo J; Icardi G; Petersen LK; Tran C; Thomas S; Luxembourg A; Baudin M Pediatr Infect Dis J; 2015 Sep; 34(9):992-8. PubMed ID: 26090572 [TBL] [Abstract][Full Text] [Related]
10. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9-14 years: Results to month 12 from a randomized trial. Leung TF; Liu AP; Lim FS; Thollot F; Oh HM; Lee BW; Rombo L; Tan NC; Rouzier R; Friel D; De Muynck B; De Simoni S; Suryakiran P; Hezareh M; Folschweiller N; Thomas F; Struyf F Hum Vaccin Immunother; 2015; 11(7):1689-702. PubMed ID: 26062002 [TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. Dobson SR; McNeil S; Dionne M; Dawar M; Ogilvie G; Krajden M; Sauvageau C; Scheifele DW; Kollmann TR; Halperin SA; Langley JM; Bettinger JA; Singer J; Money D; Miller D; Naus M; Marra F; Young E JAMA; 2013 May; 309(17):1793-802. PubMed ID: 23632723 [TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and Safety of Extended-Interval 2-Dose Regimens of 9vHPV Vaccine. Klein NP; Wiesner A; Bautista O; Group T; Kanu K; Li ZL; McCauley J; Saxena K; Tota J; Luxembourg A; Bonawitz R Pediatrics; 2024 Aug; 154(2):. PubMed ID: 38978512 [TBL] [Abstract][Full Text] [Related]
13. Efficacy, immunogenicity, and safety of a 9-valent human papillomavirus vaccine in Latin American girls, boys, and young women. Ruiz-Sternberg ÁM; Moreira ED; Restrepo JA; Lazcano-Ponce E; Cabello R; Silva A; Andrade R; Revollo F; Uscanga S; Victoria A; Guevara AM; Luna J; Plata M; Dominguez CN; Fedrizzi E; Suarez E; Reina JC; Ellison MC; Moeller E; Ritter M; Shields C; Cashat M; Perez G; Luxembourg A Papillomavirus Res; 2018 Jun; 5():63-74. PubMed ID: 29269325 [TBL] [Abstract][Full Text] [Related]
14. The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay. Brown DR; Garland SM; Ferris DG; Joura E; Steben M; James M; Radley D; Vuocolo S; Garner EI; Haupt RM; Bryan JT Hum Vaccin; 2011 Feb; 7(2):230-8. PubMed ID: 21307649 [TBL] [Abstract][Full Text] [Related]
15. Expanded strain coverage for a highly successful public health tool: Prophylactic 9-valent human papillomavirus vaccine. Zhang Z; Zhang J; Xia N; Zhao Q Hum Vaccin Immunother; 2017 Oct; 13(10):2280-2291. PubMed ID: 28699820 [TBL] [Abstract][Full Text] [Related]
16. Design of a Phase III immunogenicity and safety study evaluating two-dose regimens of 9-valent human papillomavirus (9vHPV) vaccine with extended dosing intervals. Teppler H; Bautista O; ; Flores S; McCauley J; Luxembourg A Contemp Clin Trials; 2021 Jun; 105():106403. PubMed ID: 33857679 [TBL] [Abstract][Full Text] [Related]
17. Randomized Open Trial Comparing 2-Dose Regimens of the Human Papillomavirus 16/18 AS04-Adjuvanted Vaccine in Girls Aged 9-14 Years Versus a 3-Dose Regimen in Women Aged 15-25 Years. Puthanakit T; Huang LM; Chiu CH; Tang RB; Schwarz TF; Esposito S; Frenette L; Giaquinto C; McNeil S; Rheault P; Durando P; Horn M; Klar M; Poncelet S; De Simoni S; Friel D; De Muynck B; Suryakiran PV; Hezareh M; Descamps D; Thomas F; Struyf F J Infect Dis; 2016 Aug; 214(4):525-36. PubMed ID: 26908726 [TBL] [Abstract][Full Text] [Related]
18. Antibody persistence and evidence of immune memory at 5years following administration of the 9-valent HPV vaccine. Guevara A; Cabello R; Woelber L; Moreira ED; Joura E; Reich O; Shields C; Ellison MC; Joshi A; Luxembourg A Vaccine; 2017 Sep; 35(37):5050-5057. PubMed ID: 28789851 [TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of bivalent HPV vaccine among partially vaccinated young adolescent girls in Uganda. LaMontagne DS; Mugisha E; Pan Y; Kumakech E; Ssemaganda A; Kemp TJ; Cover J; Pinto LA; Safaeian M Vaccine; 2014 Oct; 32(47):6303-11. PubMed ID: 25218297 [TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial. Neuzil KM; Canh DG; Thiem VD; Janmohamed A; Huong VM; Tang Y; Diep NT; Tsu V; LaMontagne DS JAMA; 2011 Apr; 305(14):1424-31. PubMed ID: 21486975 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]